Updated Guidance And Royalty Pharma Financing Demolish Short Thesis For BioCryst PharmaceuticalsSeeking Alpha • 02/07/22
BioCryst Pharmaceuticals: Updates To Thesis, Clinical And Commercial Momentum AcceleratingSeeking Alpha • 02/03/22
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual MeetingGlobeNewsWire • 02/01/22
BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNHGlobeNewsWire • 01/07/22
BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNHGlobeNewsWire • 11/29/21
BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, OrladeyoBenzinga • 11/22/21
BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital MarketsGlobeNewsWire • 11/22/21
BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (berotralstat)GlobeNewsWire • 11/05/21
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key MilestonesGlobeNewsWire • 11/03/21
Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/27/21